States reject Trump's offer for lower prices on weight-loss drugs

In the United States, many states have rejected the Trump administration's offer to negotiate lower prices for weight-loss drugs under Medicaid. This decision comes as states face rising costs associated with GLP-1 medications, which have seen Medicaid spending increase significantly. California, for example, has stopped covering these drugs for weight loss due to projected costs reaching $800 million by 2028-29. While Indiana has agreed to participate in the program, most states are hesitant, citing budgetary pressures and the need for legislative appropriations.